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A Review on Tumor-Treating Fields (TTFields):
Clinical Implications Inferred From
Computational Modeling
Cornelia Wenger , Pedro C. Miranda , Ricardo Salvador , Axel Thielscher, Zeev Bomzon,
Moshe Giladi, Maciej M. Mrugala, and Anders R. Korshoej
Abstract—Tumor-treating fields (TTFields) are a cancer
treatment modality that uses alternating electric fields of
intermediate frequency (∼100–500 kHz) and low intensity
(1–3 V/cm) to disrupt cell division. TTFields are delivered by
transducer arrays placed on the skin close to the tumor and
act regionally and noninvasively to inhibit tumor growth.
TTFields therapy is U.S. Food and Drug Administration
approved for the treatment of glioblastoma multiforme, the
most common and aggressive primary human brain cancer.
Clinical trials testing the safety and efficacy of TTFields
for other solid tumor types are underway. The objective
of this paper is to review computational approaches used
to characterize TTFields. The review covers studies of the
macroscopic spatial distribution of TTFields generated in
the human head, and of the microscopic field distribution
in tumor cells. In addition, preclinical and clinical find-
ings related to TTFields and principles of its operation are
summarized. Particular emphasis is put on outlining the po-
tential clinical value inferred from computational modeling.
Index Terms—Cancer treatment, computational modeling
and simulation, finite element models, tumor-treating fields
(TTFields).
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I. INTRODUCTION
A. Electric Field Interactions With Biological Tissue
I T IS WELL established that electric fields (EFs) affect cel-lular function. Direct current or low-frequency alternating
fields (<1 kHz) affect the polarization of cell membranes [1] and
induce excitatory or inhibitory effects on electrically excitable
tissue. Thus, medical applications utilizing low-frequency fields
target a multitude of diseases in a range of tissues, including neu-
ral and muscle tissue [1]. High-frequency fields (MHz range) do
not induce membrane polarization but rather cause fast oscilla-
tion of polar molecules (friction) [2] leading to tissue heating.
Therefore, high-frequency electromagnetic fields are used for
applications, such as diathermy and tissue and tumor ablation
[3]. Until recently the intermediate frequency range of several
hundred kHz had not been considered for medical applications,
since currents in this range alternate too fast to stimulate nerves
or muscles and induce only minute heating through ohmic and
dielectric loss [4]. However, since the early 2000s, several stud-
ies have shown that intermediate frequency fields disrupt cell
division in cancer cells [5], [6]. These observations have led to
the development of tumor-treating fields (TTFields) [5], [6], a
physical modality for treating cancer.
B. TTFields: Preclinical Observations and Mechanisms
of Action
TTFields are alternating EFs in the frequency range of 100–
500 kHz and intensities typically in the range 1–3 V/cm [5] that
exert an antimitotic effect on cells. TTFields have been studied
in vitro using several preclinical laboratory research systems
that have been developed for this purpose. These systems in-
clude the Inovitro system (Novocure Ltd.) [7], which consists
of a TTFields generator connected to a set of ceramic petri
dishes, microfluidic devices [8], and wire-based devices [5],
[9], [10]. Using these types of devices, researchers have shown
that exposing cells to TTFields leads to prolonged mitosis, the
formation of abnormal mitotic figures, and mitotic cell death
[5], [11], [12]. TTFields also induce violent membrane blebbing
during telophase, which in turn leads to the formation of abnor-
mal daughter cells and induction of cell death in the following
interphase [5], [13]. The antimitotic effect of TTFields is syn-
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ergistic with the effects of chemotherapeutic agents [14]–[16].
When combined with TTFields, chemotherapeutic agents deliv-
ered at doses well below the therapeutic threshold lead to com-
plete cell cycle arrest [14]. Pavesi et al. showed that TTFields
application leads to reduced proliferation of breast cancer
cells, whilst leaving normal human endothelial cells largely
unaffected [8]. Recent studies have also demonstrated that
TTFields can inhibit cell migration [9] and DNA damage repair
[10], [17].
TTFields effect is intensity dependent. Cell growth rate de-
creases as field intensity increases. For most cell lines, growth
rates begin to decrease when the field intensity exceeds a thresh-
old of about 1 V/cm, and growth is completely arrested when
field intensity exceeds about 2.5 V/cm [5], [6]. The effect is
also frequency dependent, and each cell line has an optimum
frequency, at which the inhibitory effect on cell growth is most
significant [5], [6]. For glioma cells, the optimal frequency is
200 kHz [5], [6]. In addition, cells dividing parallel to the field
are more likely to be affected by the field than cells dividing in
other directions [6], and periodically switching the field between
two orthogonal field directions was shown to be 20% more ef-
fective compared to applying TTFields in a single direction [6].
Finally, cells with a short doubling time are more susceptible to
the effect TTFields [12], likely due to the higher frequency of
mitotic events in a given time.
It has been proposed that TTFields exert their effect by caus-
ing alignment of proteins with large dipole moments with the
EF [5], [6], thereby disrupting structures and inhibiting pro-
tein polymerization. Indeed, two proteins with large dipole mo-
ments, tubulin dimers (1740 Debye [18]) and septin (2711 De-
bye [13]) are affected by TTFields. Studies show that TTFields
disrupt microtubule (MT) polymerization, preventing proper
chromosome segregation during mitosis [12], and that under
the influence of TTFields, septin, which serves as scaffold for
the actin myosin ring closing the cytokinetic furrow, fails to
localize to the cell mid-zone leading to ectopic blebbing and
abnormal mitosis [13].
To explain the effect of TTFields, it has also been suggested
that when TTFields are applied to cells during telophase, the
hourglass shape of the dividing cell causes the EF within the
cell to become highly nonuniform with higher field intensities
close to the narrow furrow region. Such field inhomogeneity
results in dielectrophoretic (DEP) forces [19] possibly leading to
irregular aggregation of polarizable particles, thereby disrupting
cell division [4], [5].
These two theories were recently evaluated in a theoreti-
cal analysis by Tuszyn´ski et al. [20]. According to this anal-
ysis, the DEP forces that develop during telophase are indeed
strong enough to interfere with mitosis. However, the forces
and torques that the EF exerts on the intrinsic dipoles of tubu-
lin are too small to have a significant effect on tubulin align-
ment. This analysis demonstrates that although the biologi-
cal effects of TTFields on cells are well documented, there
is still a need for in-depth biophysical studies to elucidate the
physical mechanisms by which TTFields exert their biological
effects [21].
C. TTFields: Clinical Trial and Clinical Settings
The clinical application of TTFields has been tested in an-
imal models [5]–[7], [11], [22], [23] and several clinical tri-
als, the first of which demonstrated that exposure to TTFields
led to local regression of skin metastases from breast cancer
and melanoma [24]. A pilot trial with patients suffering from
glioblastoma multiforme (GBM) showed that treatment with
TTFields is feasible and well tolerated without causing seri-
ous adverse effects [25]. A subsequent phase III clinical trial
(EF-11) compared the efficacy of TTFields to the physician’s
best choice of chemotherapy in recurrent GBM patients [26].
This trial showed comparable efficacy between the two arms
with a better quality of life and less toxicity for TTFields pa-
tients [26] leading to the U.S. Food and Drug Administration
(FDA) approving TTFields for the treatment of recurrent GBM
in 2011. The subsequent EF-14 trial showed that treating newly
diagnosed GBM patients with a combination of TTFields and
temozolomide led to a 5 month increase in median overall sur-
vival (hazard ratio 0.65, p < 0.00005) relative to patients treated
with temozolomide alone [27]–[29]. TTFields combined with
temozolomide was approved by the FDA for the treatment of
newly diagnosed GBM in October 2015.
Clinical trials testing feasibility and safety and/or efficacy
of applying TTFields to nonsmall cell lung cancer (Lunar
[30], [31]), pancreatic (Panova—NCT01971281 [32]), ovarian
cancer (Innovate—NCT02244502), mesothelioma (Stellar—
NCT02397928), and brain metastasis (Metis—NCT02831959,
Comet—NCT01755624) have also been initiated.
When treating GBM, TTFields are delivered using the Op-
tune system (Novocure Ltd). The system weighs 1.3 kg and
comprises a portable battery powered field generator, which is
connected to two pairs of transducer arrays placed on the shaved
scalp of the patient. One pair of arrays is placed on the left and
right sides of the head (LR array), and the other pair on the an-
terior and posterior aspects of the head (AP array). Each array
consists of nine ceramic disks arranged in a 3× 3 configuration
[33]. The device delivers a maximum current of 2000 mA peak-
to-peak at a frequency of 200 kHz. At any given instance, the
current is delivered to only one pair of arrays, and the direction
of the field is switched between the pairs of arrays once per
second. Patients are treated outside the hospital environment
and advised to wear the device for a minimum of 18 h per day
to ensure effective treatment [33]. The transducer arrays are
disposable and replaced every few days [33], [34]. The same
principles apply to treatment of other body regions, with the
frequency of the field and the geometry and positioning of the
transducer arrays adapted for each application. For instance, in
clinical trials, lung cancer is treated using the NovoTTF-100L
device, which delivers TTFields at 150 kHz and is configured
with larger transducer arrays than the Optune device [31], [35].
The placement of Optune transducer arrays on the patient’s
scalp (referred to as layout) is determined using the NovoTAL
system [36], [37]. NovoTAL uses measurements of the head
and tumor obtained from axial and coronal MR images of the
patient to derive array layouts that maximize the field delivery
to the tumor. Treatment planning with NovoTAL was defined
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as part of the protocol for the EF-14 trial, and is standard when
initiating TTFields treatment [36]. Computational studies have
shown increased EF delivery to the diseased region [38], [39]
when arrays are adapted to the individual tumor location.
D. Article Motivation and Purpose
Many factors are known to influence the outcome of GBM
treatment. These factors include age, Karnofsky performance
status, the extent of the resection, and morphological, histo-
logical, and genetic characteristics, such as isocitrate dehydro-
genase (IDH) and O(6)-methylguanine-DNA methyltransferase
(MGMT) tumor mutation status [40], [41]. When treating with
TTFields, it is reasonable to assume that in addition to the fac-
tors mentioned above [21], the distribution and intensity of the
induced EF in the brain and tumor also influence treatment out-
come. The field distribution and intensity may vary significantly
between individuals depending on the size, shape, and electri-
cal properties of the head, brain, and tumor. It would be highly
desirable to measure the field intensities in the regions of inter-
est. However, presently this task remains challenging. Hence,
numerical simulations are the best available tool for evaluating
TTFields distributions within patients.
In this paper, we will review computational studies analyz-
ing the application of TTFields. We will show how model-
ing TTFields at the cellular level can be used to investigate
the biophysical basis for TTFields mechanisms of action, and
how realistic human head models can be used to investigate the
connection between EF distribution and efficacy and safety of
TTFields treatment. We will discuss how, in the future, these
models could be employed to study treatment response, predict
progression patterns, conduct retrospective outcome analysis,
enable prospective personalized treatment planning, and possi-
bly help to select suitable candidates for therapy.
II. COMPUTATIONAL MODELS OF TTFIELDS
Whether simulating TTFields delivery at the cellular scale
(see Section II-A) or at the full head scale (see Section II-B), the
EF distribution is approximated by applying volume conductor
models [1] to numerically solve derivatives of Maxwell’s equa-
tions of electrodynamics with appropriate boundary conditions
(BCs). For TTFields, the electromagnetic wavelength is much
larger than the size of the models, and therefore the electro-
quasistatic approximation of Maxwell’s equations may be ap-
plied [42]. Thus, the electric potential V can be found by solving
the Laplace equation, ∇ · σ˜∇V = 0. Here, σ˜ = σ + iωε is the
complex conductivity, ε is the permittivity, σ the electrical con-
ductivity, and i the imaginary unit, and ω = 2πf the angular fre-
quency. The numerical task of solving the Laplace equation can
be achieved using, for example, the finite element (FE) method.
Table I illustrates the similarities and differences between cel-
lular scale and full head scale models for studying TTFields.
A. Cellular Level Modeling
1) Materials and Methods: Glioma cells have been found
to round up during mitosis to a sphere of approximately 5500 fL
TABLE I
COMPUTATIONAL MODELING OF TT FIELDS APPLICATION
Cellular level model Human head model
purpose study of TTFields
mechanism of action
study of TTFields clinical
application
related device Inovitro Optune
model creation simple geometric
objects
MRI tissue segmentation
model physics electro-quasistatic
approximation of
Maxwell’s equations
electro-quasistatic
approximation of Maxwell’s
equations
model result EF distribution in the
extracellular space,
the cell membrane,
and cytosol
EF distribution in the head
and tumor tissues
Fig. 1. Ei distribution in the metaphase cell (column1) and three stages
of telophase (columns 2–4) for varying frequency (rows) of the applied
EF from left to right with an intensity of 1 V/cm. The color scale is fixed
for all panels from 0–2.5 V/cm. The bottom panel illustrates the furrow
length (red line) and spherical ROI (blue circle) in the telophase cells.
(radius of approximately 11 μm) [43]. According to images of
the division process [43], as the cell proceeds into telophase
elliptical cell shapes with equal size become more appropriate
to characterize the process in which the daughter cells form.
To reflect these geometries, studies simulating TTFields ap-
plication to single cells [20], [44]–[46] assumed a spherical
cell with a default radius of 10 μm during metaphase. During
telophase and cytokinesis, elliptical sister cells with a default
major radius of 10 μm and a minor radius of 7 μm were con-
sidered. Three different stages of telophase were modeled by
decreasing the length of the incision plane between the sister
cells (furrow length) as division progressed (see red line in the
bottom panel of Fig. 1).
The models comprised of three domains: the extracellular
space, the cytosol, and the membrane, which differ in their
dielectric properties. The standard values assigned to these tis-
sue types were σi = 0.3 S/m, σe = 1.2 S/m, σm = 3e–7 S/m,
εi = 72.3, εe = 72.3, εm = 5. These values were adapted from
computational studies conducting similar investigations [47]–
[56]. Since a large range of properties are expected within the
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Fig. 2. Maximum Ei as a function of frequency for four different cell
cycle stages. The values are measured in central ROIs with a radius of
80% of the furrow length.
population of glial cells [46], different ranges of these param-
eters were tested to investigate how the dielectric properties of
cells influence their response to TTFields (see Section II-A-2).
The computational studies [20], [44]–[46] were carried out using
the Electric Currents Interface of the ac/dc module of Comsol
Multiphysics (www.comsol.com). The thin membrane was nu-
merically represented by the contact impedance BC available in
Comsol.
In order to apply a homogenous EF, the BCs on two opposite
sides were chosen as terminals of the voltage type where the
others were electrically insulated, representing an ideal parallel
plate electrode setup. The default applied voltages of oppo-
site signs were chosen to produce standard field intensity of
1 V/cm, which corresponds to the minimum activity threshold
of TTFields intensity. The computational model was validated
by comparing numerical results for a spherical cell to the ana-
lytical description of the transmembrane voltage of a spherical
cell with radius r (data not shown) [52].
2) Results
a) Effect of field frequency: The distribution of the
EF intensity in and around a cell with standard geometric and
dielectric properties (see Section II-A-1) is plotted in Fig. 1
for selected frequencies (rows) at different stages of mitosis
(columns). For a round cell during metaphase, the EF distri-
bution inside the cell is uniform with only small perturbations
close to the membrane. The intracellular field intensity, Ei al-
most equals zero for frequencies <10 kHz (left top in Figs. 1
and 2). For increasing frequency, Ei gradually increases and fi-
nally equals the applied field intensity for frequencies >1 GHz
as predicted by Figs. 1 and 2 and discussed in detail elsewhere
[45], [46].
During telophase, the low-frequency fields do not penetrate
the membrane and Ei is close to zero (column 2 in Figs. 1
and 2). However, as frequencies increase into the kHz range, a
nonuniform field develops within the cytosol with higher field
intensities found close to the furrow between the dividing cells
(see columns 2–4 in Fig. 1). The most pronounced and spa-
tially confined EF at the furrow is found for a stage3 cell (see
column 4 in Fig. 1). As the frequency of the field increases,
the nonuniformity close to the furrow decreases and the field
intensity throughout the cell increases. Thus, Ei peaks between
100–500 kHz during telophase, with lower peak frequencies
observed for later stages of cell division (see Fig. 2).
For this review article, we evaluated the maximum of Ei in a
spherical region of interest (ROI—blue circles in bottom panel
of Fig. 1) located at the center of each cell, with a diameter
that corresponds to 80% of the furrow length (see Fig. 2). The
figure shows that the maximum value of Ei increases as the cell
progresses through cell division and that its value can exceed
the external field strength of 1 V/cm. Second, the frequency for
which the maximum Ei occurs decreases as the cell division
progresses (see Fig. 2). As a result of the field inhomogeneity
inside the dividing cell, the gradient of the EF becomes nonzero.
Hence, the DEP force component defined as ∇|Ei |2 [57], [58]
also takes on nonzero values, increasing to maximal values dur-
ing later stages of telophase with highest values for stage3.
b) Effect of cell size: Subsequently, we investigated
how the geometric and dielectric properties of the cell influence
the EF distribution. Fig. 3 shows the maximum of Ei as a func-
tion of frequency for cell radii r = {4, 10, 15, 20 μm}. During
metaphase the biggest cell with r = 20 μm has the highest Ei
for all field frequencies, (see Fig. 3(a)), and the peak frequency
at which the highest Ei is found in a cell (10 MHz) is unaf-
fected by cell radius. During telophase the biggest cell has the
highest Ei only for low frequencies [see Fig. 3(b)–(d)]. As the
cell radius increases, maximum values of Ei occur at lower
frequencies [see insets of Fig. 3(b)–(d)]. When a constant field
frequency of 200 kHz is applied, cell size influences the field
exposure inside the cell (see vertical lines in Fig. 3). During
metaphase and stage1 [see Fig. 3(a) and (b)], the highest Ei is
found in the biggest cell and the lowest Ei in the smallest cell,
whereas for stage2 and stage3 the maximum Ei is found in cells
of smaller size [see Fig. 3(c) and (d)].
It is interesting to note that the differences in the maximal
values of Ei obtained at different cell sizes are smaller than 3%,
as shown by the similar height of curves in Fig. 3 and the dotted
lines in Fig. 4. This might suggest that the effect of TTFields
can be maintained if the frequency is tuned to match the cell
size. However, the simulations show that the magnitude of the
DEP force component |∇|Ei |2 | is inversely proportional to the
cell size, likely leading to less effective exposure for bigger cells
(see the solid lines in Fig. 4).
c) Effect of cell’s dielectric properties: Previous
computational studies predicted that the dielectric properties, σ
and ε, of the cell are important determinants of the values of Ei
and|∇|Ei |2 |. The most influential parameters were found to be
σi , σm , and εm , details can be found in [45] and [46]. For all
parameter variations, peak frequencies varied between 125 kHz–
1 MHz for stage1, 50–400 kHz for stage2, and 50–250 kHz for
stage3. Another consequence of changing the cells dielectric
parameters is that for a fixed field frequency of 200 kHz, induced
values of Ei and|∇|Ei |2 | might differ significantly.
Apart from the cell’s intrinsic geometric and dielectric prop-
erties, the intensity and direction of the externally applied EF
influence the EF distribution inside and around the cell. The
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Fig. 3. Maximum Ei as a function of frequency for four selected cell
sizes (a) during metaphase and different stages of telophase (b)–(d).
The insets in (b)–(d) plot the peak frequency as a function of cell radius,
corresponding peaks of the four selected cells are marked as black
diamonds on the curves. The vertical line marks 200 kHz and the span
of values is emphasized in red.
induced values of Ei increase proportionally with the increasing
field intensity and the DEP force component exhibits a quadratic
growth [44].
d) Effect of cell orientation: The connection be-
tween the orientations of dividing cells relative to the field has
also been investigated. The field’s orientation to the spherical
metaphase cell does not change Ei . The intracellular field re-
mains uniform with parallel EF lines perpendicular to the ap-
plied field. But when the cell shape becomes irregular during
telophase, the angle between the division axis of the cell and
the applied field has significant impact on the intracellular field
distribution. The higher the angle between the furrow and the
field, the lower the induced maximum Ei within the cell. This
is true for frequencies below 1 MHz, after which the behavior is
Fig. 4. For each tested cell radius (r = 4–20 μm), the normalized
maximum of |∇|Ei |2 | is plotted as solid lines (left primary axis) and the
maximum of Ei as dotted lines (right secondary axis). Values measured
in central ROIs.
Fig. 5. Ei distribution induced in a cell during three stages of telophase
(columns) for varying angle between the division axis and the EF (rows).
The field has a frequency of 200 kHz, an intensity of 1 V/cm, and it
is applied from left to right. The maximum Ei in a spherical ROI (white
circle) is presented in each panel in white and the corresponding average
Ei in the whole cell in black.
reversed (results not shown). As example, Fig. 5 plots the field
distribution at 200 kHz for the 3 stages (columns) and 5 different
angles from 0° to 90° (rows). The decreasing maximum values
within the spherical ROIs (white circle in Fig. 5) are printed
in the panels. Furthermore, the average EF within the whole
cells also decreases (see the black values in Fig. 5). In each
column, the Ei in the highly exposed furrow region diminishes
as the angle between division axis and field increases from top
to bottom.
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e) Discussion and future directions: The ultimate
goal of the computational models presented above is to provide
insight into the biophysical mechanisms that govern TTFields,
starting with the examination of the connection between the in-
tracellular field distribution and the field parameters (mentioned
in Section I-B) that influence treatment efficacy.
Field frequency: Experimental results predict that the effi-
cacy of TTFields is frequency dependent and each cell line has
a specific frequency for which the inhibitory effect is highest
[5]. Additional in vitro experiments predict that the optimal fre-
quency for the inhibitory effect of TTFields is inversely related
to the cell size [5], [6]. The computational models confirm that
during cell division, the EF intensity peaks in the range between
100 and 500 kHz with a lower peak frequency for later stages of
telophase (see Fig. 2). It should be noted that the target cells are
all in different stages of mitosis in a patient, and therefore there
is probably no single frequency that is optimal for all of the cells.
However, even if one were to be able to synchronize the target
cells to be in stage3 for instance, it might not increase the thera-
peutic effect of TTFields delivered at a single frequency because
of potentially other yet undiscovered biological processes.
The computational models further predict that the cell’s
geometric (see Fig. 3) and dielectric properties influence the
reported peak frequencies. Because different cell lines have dif-
ferent properties, the simulation results might explain the cell-
line specific optimal frequency. It would be insightful to evaluate
and measure the size and dielectric properties of different cell
lines [59] and compare them to the computational results. The
modeling results show that with increasing the cell size the peak
frequencies decrease [see insets Fig. 3(b)–(d)]. The correspond-
ing maximum values of |∇|Ei |2 | also decreases with the cell
size. It is worth noting that experiments showed that cell vol-
ume increases in almost all cell lines treated with TTFields [60].
Thus, increasing the cell size during TTFields treatment might
be an escape mechanism of the cancer cells, because the intracel-
lular field and DEP component decrease as the cell size changes.
Field Intensity: TTFields’ effect increases with intensity [5],
and higher field intensities yield smaller cell counts. The com-
putational modeling confirms that increasing the field’s intensity
also increases the induced intracellular field and DEP compo-
nent [44]–[46].
Direction of division: In line with experimental results,
the computational model predicts decreased intracellular field
strengths for cells that are not dividing parallel to the applied
field.
When evaluating these results, it is important to keep in
mind that the models represent single isolated cells with a ho-
mogeneous cytoplasm. Yet, within tissue, cells are generally
packed, which could cause local inhomogeneity in the extra-
cellular fields, and could to some extent attenuate field distri-
butions. However, the degree to which TTFields penetrate the
cells is determined by the properties of the single cell. Thus, it
is unlikely that the observation that the intracellular field and
DEP depend on the frequency, intensity, and direction of the
applied field will change when considering models of packed
cells. Additionally, the cytoplasm is heterogeneous and contains
multiple organelles which would increase the nonuniformity of
intracellular fields. This could possibly lead to local field gra-
dients and DEP forces even when the cell is rounded during
metaphase. Thus, cytoplasmic heterogeneity is expected to mag-
nify the effects of TTFields.
Let us now turn our attention to how the intracellular EF
might disrupt mitosis. Endogenous EFs are believed to play a
key role during mitosis [61], [62] as supported by experimen-
tal evidence for peak electromagnetic activity during mitosis
[63], [64] as well as by physical modeling of the electrostatic
forces generated by MTs which are at work during mitosis and
influence chromosomal motion [65]–[67]. Thus, it is not un-
likely that external EFs, such as TTFields could disrupt mitosis.
It has been speculated that when dividing cells are exposed to
TTFields, the tubulin dimers align with the field rather than with
the growing MT axis. However, Tuszyn´ski et al. [20] calculated
that the interaction energy of a tubulin dimer with an EF of 1
V/cm is too small to affect the dynamics of the dimer. They
also proposed that a 1 V/cm EF would be insufficient to exert
a major influence on MTs and the cytoskeleton due to Debye
screening. Furthermore, they showed that the torque an MT ex-
periences in a 1 V/cm field is 3 orders of magnitude too low
to lead to significant rotation. However, the authors did show
that the field nonuniformity in dividing cells could cause sub-
stantial DEP forces on tubulin dimers and MTs potentially large
enough to disrupt cell division. In addition, they showed that
under the influence of TTFields, significant ionic currents could
develop along MTs that might disrupt cellular function. In the
future it would be useful to create complex cellular models by
combining the computational models presented here with elec-
tromechanical models of mitotic spindle dynamics [68], [69].
These models have already been adapted to address possible
mechanisms of the effects of ultrashort electrical and mechan-
ical pulses on dividing cells [70]. It would also be useful to
measure the magnitude of TTFields within the cells. This task is
challenging. However, a promising technique that can measure
local EF in cell cultures has been reported [71]. In the future,
similar techniques might be applicable to experimentally mea-
sure the magnitude of TTFields within cells.
B. Realistic Human Head Modeling
1) Materials and Methods: The creation of realistic human
head models is a challenging task, which relies on the segmen-
tation of MRI datasets. Typically, the healthy human head will
be divided into tissue types of distinct dielectric properties: the
scalp, the skull, the cerebrospinal fluid (CSF), the gray matter
(GM) and the white matter (WM). The CSF filled ventricles in
the center of the head will also usually be identified. There are
many different software packages available to achieve this task
in a semiautomated manner.
a) Head model creation: The first model created
for TTFields simulation studies [72], [73] originated from T1
and proton density weighted MRIs (http://brainweb.bic.mni.
mcgill.ca/brainweb) of the Colin27 dataset. The freely avail-
able Brainsuite software was used for segmentation [74]. The
second model used a dataset of a young healthy female con-
sisting of T1, T2, and diffusion MRI (dMRI) datasets [75]. The
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Fig. 6. Example of patient-specific head model based on MRI data.
The figure shows an axial T2 MRI image (left) obtained from a 23 year
old female patient with deeply seated anaplastic astrocytoma. The three
rightmost panels show the head model and tissue segmentation, which
was created from the MRI data (T1 and T2) from the same patient. Elec-
trode positioning is evident from the surface reconstruction and elec-
trodes are paired orange/white (LR) and gray/blue (AP).
open-source package SimNibs v1 [76], which uses Freesurfer
[77] for segmenting the cortical tissues and FSL [78] for seg-
menting the outer tissue layers, was adapted for this purpose.
Brainsuite was used to create the scalp and skull segmentation
of the second model. A recent study [79] has employed a similar
approach using the almi5 dataset and the SimNibs v2 software
(www.simnibs.org). These models relied on datasets of healthy
persons, thus the presence of a tumor was modeled by incorpo-
rating virtual lesions consisting of two concentric spheres; the
inner sphere represented necrosis surrounded by an enhancing
tumor [73], [75], [79]. In [79], 24 tumors were systematically
introduced at different positions relative to the active transducer-
arrays. In [39], three more tumor locations were tested, and also
more complex shaped, bigger, more realistic dimensions were
assumed.
The first model of a patient with recurrent GBM treated with
TTFields therapy was created by segmenting structural images
with ScanIP, a commercial software [80], [81]. More recently,
head models of a patient with GBM and a patient with anaplas-
tic astrocytoma were created using T1, T2, and dMRI datasets
[82] (see Fig. 6). To create these models, T1 and T2 data were
initially processed using the mri2mesh algorithm in SimNibs v2
(www.simnibs.org) to produce a preliminary volume mesh. Sub-
sequently, the surface mesh structures and binary tissue masks
produced by the algorithm were edited manually using custom
code based on meshfix [83], FSL, and Freesurfer algorithms.
This was done in order to accurately reproduce the patient’s
anatomy, particularly in the tumor region and its immediate
surroundings.
Following segmentation, the transducer arrays have to be
modeled. The studies by Wenger et al. used the 3-matic pack-
age of the Mimics v.14 software (www.materialise.com) for this
task. The transducers were modeled as 1 mm high cylinders with
a radius of 9 mm and the gel layer was represented by cylinders
(0.5–2 mm height) of 10 mm radius. For head models created
by Korshoej et al., this step was performed automatically with a
custom-written MATLAB code (www.mathworks.com). In or-
der to complete the model for FE calculation, the final volume
mesh has to be created. For models of Wenger et al., this step was
performed with Mimics, while open-source tools in SimNibs,
Gmsh [84], and meshfix [83] were employed for the patient
models.
b) Finite element calculation of the EF
distribution: In order to solve the Laplace equation, the
virtual tumor studies used the Electric Currents physics of the
ac/dc package of Comsol (www.comsol.com). Because of the
complexity of the model, the solver had to be chosen carefully
to obtain convergence (GMRES with SOR preconditioner). For
models by Korshoej et al., FE calculations were performed with
SimNibs using GetDP with an implemented Galerkin method
[85] and residuals for the conjugate gradient solver required to be
<10−9 .
To simulate delivery of TTFields to the models, suitable BCs
have to be applied. Typically, continuity of the normal compo-
nent of the current density at all interior boundaries and electric
insulation at the external boundaries are considered. In both the
virtual tumor models and the patient-based models, the exter-
nal bases of the active transducer arrays were assigned floating
potential BCs that set the potential at that boundary so that the
integral of the normal component of the current density was 900
mA per transducer array, summing up to 1800 mA peak-to-peak
for an active pair of transducer arrays.
To complete the model, the dielectric properties of the differ-
ent tissue types have to be defined. Isotropic values of electrical
conductivity and relative permittivity of different tissue types are
listed in the corresponding articles [73], [75], [82]. Studies of
related techniques showed that incorporating the anisotropic na-
ture of electric conductivity within the WM significantly affects
results [86]–[89]. This anisotropy can be captured by processing
diffusion tensor imaging (DTI) data which estimates the diffu-
sion tensor for each voxel [90], [91]. For the second virtual tumor
model, the raw DTI images were corrected and registered with
the FSL diffusion toolbox [92] in order to calculate the principal
directions (eigenvectors), principal diffusivities (eigenvalues),
and the fractional anisotropy. There exist several ways for the
subsequent estimation of the conductivity tensor, as described
in detail elsewhere [93].
In models by Wenger et al., the direct mapping (dM) method
that assumes a linear relationship between the eigenvalues of
the diffusion and conductivity tensors was applied [94], i.e.,
σv = s · dv , where σv and dv are the vth eigenvalues of the
conductivity and the diffusion tensors, respectively. Instead of
the initially proposed empirical scaling factor s [94] which is
not generally valid, an adapted s was considered [95]. Addition-
ally, an adapted volume normalized (vN) mapping method was
used, which locally matches the geometric mean of the conduc-
tivity tensor’s eigenvalues in each voxel to the corresponding
isotropic conductivity value (either WM or GM) [96]. In order
to incorporate tissue anisotropy into the computational models,
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Fig. 7. Conductivity maps and estimation for patient-based and virtual
tumor models. (a) Axial section of dMRI based conductivity map obtained
using SimNibs. The map was created using direct linear mapping based
on the right GM and WM tissue and then extrapolating the obtained scale
factor to obtain a generalized conductivity map covering the whole brain
and tumor. (b) The corresponding probability density functions of the
conductivity estimates. (c) The fractional anisotropy distribution of the
conductivity tensors. As evident from the figures, both distributions in (a)
and (b) cover a wide range of values with considerable topographical
variability, particularly in the tumor region, which illustrates the poten-
tial importance of utilizing patient-specific estimates. It is also notable
that the conductivity range and mean values correspond well to in vivo
estimates.
the conductivity tensor of each voxel was imported into Comsol
for FE computation.
For the patient head models, dMRI processing and conduc-
tivity estimation with the DM approach was performed using
the dwi2cond algorithm in SimNibs. The scaling factor was ob-
tained by fitting only the nonpathological regions of the GM
and WM tissues of the contralateral hemisphere to standardized
values, because the technique remains to be firmly validated for
tumor tissue. Values in the tumor tissue were obtained by extrap-
olation using the obtained fit. Fig. 7(a) shows a conductivity map
obtained from dMRI data from a patient with left frontoparietal
GBM alongside the corresponding probability density functions
[see Fig. 7(c)] of the conductivity values. The mean conductivity
value in the tumor region was 0.245 S/m and the interquartile
range was 0.077 S/m. Thus, the estimated conductivity of the
tumor was in the same range as previously reported for gliomas
in vivo [97]–[99] and agreed well with the conductivity val-
ues used in the virtual tumor models. Fig. 7 also demonstrates
the considerable anisotropy (high fractional anisotropy) in the
WM tissue, which has been shown to impact the distribution
of the estimated field considerably [75]. It is also evident that
the tumor region is characterized by considerable topographical
variability in both conductivity and fractional anisotropy, which
highlights the importance of individualized head modeling and
conductivity estimation. After conductivity estimation, the re-
sulting anisotropic conductivity tensors were imported directly
into SimNibs for FE calculations.
For the virtual models by Korshoej et al., a similar approach
was adopted to produce a conductivity tensor for WM and GM
using dwi2cond algorithm. Isotropic conductivities similar to
Wenger et al. were used for the remaining tissues, including the
tumor and necrosis.
2) Results: The simulation-based studies show that
TTFields distribution within the brain is heterogeneous [72],
[73], [79], [100] and influenced by the complex tissue inter-
faces, and especially the differences in dielectric properties of
the different tissues. The highest field intensities are found in
the scalp and skull close to the active transducer arrays. Al-
though the field in the brain tissue on average decreases with
the increasing distance from the transducers, field strengths are
not necessarily higher for tumors close to the active arrays. This
is mainly due to shunting of current through surrounding less
resistive CSF pathways during LR array activation [79]. Deeper
regions with higher field intensities (hot spots) were also ob-
served (see Fig. 8), caused by the fact that at a tissue interface
the field increases in the lower conductivity medium and de-
creases in the tissue with higher conductivity. This behavior
has also been reported in other noninvasive brain stimulation
techniques [101]. In addition, the CSF creates low-resistance
pathways causing currents to flow through the sulci, ventricles,
and resection cavities toward deeper regions, which in turn cre-
ates local field “hot spots” in deeply seated tumors embedded in
WM, as well as in tumors located close to the sulcal fundi and
near resection borders [79]. Higher EF intensities were found
for the LR array and the field distribution appears to be more
uniform in the AP setting. Nonetheless, the average EF inten-
sities in the brain were estimated to be very similar in the two
settings, |ELRbrain | = 1.18 V/cm and |EAPbrain | = 1.14 V/cm [75].
The AP array configuration delivered higher field intensities to
superficial tumors, while the LR configuration delivered higher
intensities to deeper tumors [79].
Within the tumor, low field values were found in the necrotic
core and higher values with a nonuniform distribution were
found in the tumor and peritumoral border zone [73], [79].
Again the directional effects, explained above, were respon-
sible for hotspots created in the tumor, which were far more
pronounced in the LR setting for the first tumor location tested
[75]. The average EF intensities in the enhancing tumor part de-
pended significantly on the tumor location and ranged between
|ELRshell| ≈ 1.20 − 1.65 V/cm and |EAPshell| ≈ 0.75 − 1.40 V/cm
[75], [79].
Another aim of the modeling studies was to clarify to what
extent the EF distribution depends on assumptions about the di-
electric properties of the tissues, and the extent to which tissue
anisotropy influences the field distribution [75], [100]. For the
second virtual tumor head model, representation of the conduc-
tivity tensor using both the dM and the vN methods (see Section
II-B-1) yielded field distributions that were similar to the field
distribution in the isotropic model. The calculated average EF
intensities in the brain and tumor showed only minor differences
between isotropic and anisotropic models. However, tumor lo-
cations in highly anisotropic areas of the WM [79] and possibly
also the tumor’s intrinsic anisotropy of conductivity can influ-
ence the field intensity at the diseased site. Indeed, the field
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Fig. 8. Distribution of the EF’s intensity (V/cm) is presented in two axial slices through a virtual tumor located frontal in the left hemisphere (contour
shown in the left hemisphere, anteriorly). Default (second row) and patient-specific adapted layouts (third row) are presented for LR and AP setups
of the Optune device. Corresponding anatomical slices and their position in the head model are presented at the top. Reproduced from [38].
distributions in the patient-based models suggest that the choice
of conductivity assignment plays a significant role in determin-
ing the field distribution in the regions of pathology. Particularly,
the median field intensity is approximately 0.20 V/cm lower in
the peritumoral border zone for the patient shown in Fig. 7
when the dM anisotropic conductivity tensor is used compared
to isotropic scalar conductivity assignment. In WM, GM, and
tumor tissue, no significant differences in the central tenden-
cies of the field estimates were observed although the choice
of conductivity model did affect the topographical distribution
of the field in all tissues. Specifically, the interquartile range
of the paired difference in field estimates for all elements was
>0.40 V/cm for all tissues. The fact that the peritumoral region
is more sensitive to the chosen conductivity model, likely indi-
cates that standardized conductivity values for GM and WM do
not accurately represent the tissue properties in this region due
to the presence of edema and tumor infiltration.
Furthermore, a sensitivity analysis has been carried out to de-
termine how uncertainties in the dielectric properties of tissues
affect the EF in the tumor [75], [100]. Variations of permittivity
values by up to twofold in all of the head tissues lead to changes
in the average field intensity of less than 2% [75]. This is due to
the fact that for TTFields settings the current is mainly resistive
as opposed to capacitive, i.e., σ  ωε0εr [102]. Furthermore,
this result validates the approach of considering a static prob-
lem by neglecting the permittivity, as it was done in the patient
studies using SimNibs. However, significant differences in the
induced EF intensities have been observed when conductivity
values of both pathological and healthy tissues are varied by up
to 2.5-fold [75]. The percentage difference between the highest
and the lowest average field intensity in the brain changes up to
42%. Within the tumor the differences in field intensities can be
as large as 68%. The tissues whose conductivity has the greatest
effect on the average EF in the tumor are the tumor itself, the
skull, and the scalp [75].
The influence of tumor composition on the field intensity was
also investigated [79], [100], [103]. The virtual cystic tumors
discussed above (with a necrotic core) were replaced with a solid
enhancing tumor mass [79], [103]. Although the average field
intensity in the active part of the tumor is similar in both cases,
the EF distribution is relatively uniform in the solid tumor, but
shows hot spots and less exposed areas within the active region,
when a necrotic core is introduced.
A consecutive study investigated the influence of tumor size,
shape, and position on EF intensity [39]. A virtual tumor with the
same shape and size as the tumor discussed above was placed at
different location within the brain. Two additional tumors with
irregular shape and larger sizes were placed in the left hemi-
sphere (see Fig. 8). The computational results show that tumor
shape and size, up to 26.6 cm3 total volume, did not have a no-
ticeable impact on the average EF intensity in the tumor, owing
primarily to the large size of the individual arrays. Simulations
revealed that the induced average EF intensity value remained
above 1 V/cm for all tumors irrespective of the direction from
which TTFields was delivered. However, visual examination of
the field distribution suggested that the default position of the
arrays tested in these simulations might not deliver optimal field
intensities to all tumors. Tumors in the anterior region are not
well covered by the default LR array placed above the ears, al-
though their proximity to the frontal AP patch has been shown to
induce high field intensities (see Fig. 8). For superficial tumors,
the patches are too low to induce optimal field delivery. The
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study therefore investigated how adapting the transducer arrays
positions to specific tumor location influenced field intensity.
Indeed, for all tumor locations, moving the patches closer to the
region containing the tumor increased the induced average EF
intensity in the tumor (see Fig. 8). Details can be found in [39].
Since there exist models of two individuals with the same
virtual tumor in terms of size, position, and properties, conclu-
sions about patient variability can be drawn [75], [104]. The
second model generally showed higher EF intensities, with av-
erage values 20% and 50% higher for LR and AP configurations,
respectively. The two heads have different shape and size (the
first model head is bigger), and an exploratory analysis showed
that the median thickness of the scalp and skull are 94% and
75% smaller, respectively, in the second model. Thickening the
skull in the second model and increasing the head size of the
second model [39] bring the average EF intensities in the tumor
closer to the values observed in the first model. These studies
illustrate the large extent to which the individual head shape and
size, and the geometry and thickness of the tissue compartments
[100] influence TTFields distribution within the head.
3) Discussion and Future Directions: Currently, there are
no noninvasive methods to image the induced TTFields in the
head during therapy. Only one intracranial measurement of
TTFields intensity has been performed on a human subject.
This measurement showed that TTFields intensity within the
center of the brain ranges between 1 and 2 V/cm, and is within
10% of the predicted values [6]. The development of realis-
tic human head models has allowed detailed description of EF
distribution in the head following Optune treatment. This is an
important step toward understanding the basic features of the in-
duced field, which are not entirely intuitive. The induced field is
highly nonuniform and depends on the complex tissue interfaces
and their dielectric property distributions. This results in regions
of high field intensity not only close to active transducers but
also in deep areas of the brain.
Realistic computational models have also enabled quantifi-
cation of the EF intensity delivered to the tumor, and show
that TTFields intensity in large regions of tumors exceeds the
therapeutic threshold of 1 V/cm, irrespective of head geome-
try, tumor location and size, and array configuration. The field
estimates are influenced by model uncertainties, particularly
by uncertainties of the chosen ohmic tissue conductivities. The
conductivity is frequency dependent [105] and the intermediate
frequency range is least studied and experimental results often
cover the low-frequency or higher frequency regimes. In addi-
tion, the values reported in the literature possess a substantial
spread. Given that the computational study employing a virtual
tumor model demonstrated a clear sensitivity of the calculated
fields on the chosen tissue conductivities, specific measurements
would be highly desirable and would certainly provide an op-
portunity to improve the accuracy and precision of the model
results. This not only relates to the conductivity of the main
tissues (skin, skull, CSF, brain gray and white matter), but also
to the conductivity of the tumor tissue, which might possess
a wide interindividual spread due to differences in tumor type
and “stage of development.” The latter notion is supported by
the documented interindividual variation in apparent diffusion
coefficient (ADC) in the tumor region and also the established
correlation between ADC values and glioma grade [106].
Virtual tumor models have the advantage of being versatile
and able to simulate virtually every situation in terms of tu-
mor location, shape, and size, as well as head shape and size.
The influence of each of these parameters can be studied sys-
tematically. One study investigated adapting transducer arrays
to specific tumor locations, to clarify how beneficial the treat-
ment planning with NovoTAL might be. The modeling results
confirmed that the EF intensities can be significantly increased
when a patient-specific array layout is used. However, only one
subject was tested with virtual tumors and another study al-
ready predicted differences in the induced field for two different
persons. Computational modeling has the potential to identify
the properties of the head that result in these differences. One
small study started to investigate the effect of different head size
and thicknesses of outer tissue layers. It would be possible to
deform the virtual tumor model into different shapes and scale
tissue to produce a more individual model [107]. However, these
techniques might underestimate altered anatomy due to disease
(edema, midline shifts, etc.) in a real patient.
Thus, patient head models, which are created by directly seg-
menting patient MRI datasets, are a highly important addition
to the computational simulation of TTFields application in clin-
ical settings. Such patient-specific models have recently been
applied in a study aiming to investigate the potential benefit of
combining TTFields with surgical craniectomy [82]. A clinical
phase I trial testing the safety and feasibility of this procedure
was recently launched (NCT02893137). This example high-
lights how computational modeling can facilitate translational
research.
Despite the considerable potential of patient-specific models,
further investigations are required to firmly validate the tech-
nique. An important aspect will be the further validation of the
dMRI approach for conductivity estimation on a larger number
of patients, potentially by correlating dMRI estimates of con-
ductivity to stereotactic in vivo measurements from the same
patient [82].
Furthermore, ongoing studies by the authors aim to character-
ize the importance of tumor locations and morphological char-
acteristics, such as size, shape, mean conductivity distribution,
and fractional conductivity anisotropy, on the distribution of the
induced field [82]. Such an investigation would be an important
addition to the studies performed with the virtual head models,
because of the valuable insight on the tumor’s heterogeneous
environment and its influence on the induced field. A recent
study presented a first attempt to create simpler head models
that can provide accurate results for calculating the EF distri-
bution for the application of TTFields [108]. However, future
feasibility studies based on a number of datasets should address
the performance of this simplified model.
Currently, the frameworks available for creating patient-
specific models are cumbersome and time-consuming [82].
This is primarily because algorithms for automatic tumor seg-
mentation are inaccurate. Hence, considerable manual interven-
tion is required to obtain models that accurately represent pa-
tients. For successful clinical implementation of future modeling
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technologies, the time required to create models and run simu-
lation should be minimized. Thus, an effort should be made to
improve segmentation and model creation algorithms to obtain
the goal of rapid patient-specific modeling; a parallel investi-
gation into how much complexity is needed in a model to pro-
duce reliable predictions of the EF distribution should also be
performed.
Clinical investigations have shown a favorable safety profile
of TTFields and Optune in particular. Already the virtual head
models were used to evaluate specific absorption rate (SAR) val-
ues in the scalp, skull, and brain tissues [73], [75]. In the patient
head models, peak SAR values were increased by craniectomy
but still within the range of median SAR values previously
reported [82]. It was concluded that the treatment would not
impose additional risk of overheating or damage of healthy tis-
sue [82]. Apart from investigating induced SAR values, these
modeling studies could also be adapted to specifically study the
heat distribution in the head from Optune treatment.
There are many avenues through which computational head
models could be used to address clinical questions. The tools
described here could be employed to conduct a retrospective
outcome analysis in which patient-specific models are created
and the connection between disease progression and field distri-
bution could be investigated. Computational models combined
with a deep understanding on how field distribution influences
disease progression could then be used for adaptive treatment
planning. Realistic head models of a patient could be created
periodically during the course of treatment, reflecting dynamic
changes in tumor morphology and tissue properties [82]. These
models could be combined with simulations and an understand-
ing of field intensity influences disease progression to optimize
TTFields delivery in a dynamic manner throughout the course
of treatment.
III. SUMMARY AND CONCLUSION
In this review, we showed how modeling at different scales
can be employed to study TTFields application. At a cellular
scale, simulation studies can be used to strengthen physical un-
derstanding and basic knowledge of cell-EF interaction. With
the creation of realistic human head model, it is possible to
investigate TTFields in clinical practice by analyzing induced
EF distributions in the patient’s brain and tumor during Optune
treatment. Important insights can be obtained from these calcu-
lations, such as retrospective analysis of treatment outcome as
well as prospective personalized treatment planning. In conclu-
sion, TTFields is yet another application, where computational
modeling acts as an integral part for further development and
efficacy improvement of a therapy. Clinical and engineering
communities will greatly benefit by collaborating and drawing
from common resources and knowledge.
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